Nishiguchi S - Search Results

1

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. Sakamoto N, et al. Among authors: nishiguchi s. Hepatol Res. 2010 Nov;40(11):1063-71. doi: 10.1111/j.1872-034X.2010.00741.x. Hepatol Res. 2010. PMID: 20977565

2

Changes in hypervariable region 1 in patients with chronic hepatitis C of genotype 1b with biochemical response to interferon.

Nishiguchi S, Tanaka M, Shiomi S, Kaneshiro S, Enomoto M, Fukuda K, Tamori A, Habu D, Takeda T, Tohdoh N, Otani S, Tatsumi N. Nishiguchi S, et al. Hepatol Res. 2002 Aug;23(4):237. doi: 10.1016/s1386-6346(01)00186-3. Hepatol Res. 2002. PMID: 12191672

3

Meshwork pattern is an important risk factor for development of hepatocellular carcinoma in patients with HBV-related chronic hepatitis and cirrhosis.

Habu D, Nishiguchi S, Kawamua E, Lee C, Enomoto M, Nakatani S, Tamori A, Sakaguchi H, Takeda T, Seki S, Ogami M, Fukushima W, Tanaka T, Asai H, Shiomi S. Habu D, et al. Among authors: nishiguchi s. Hepatol Res. 2003 Feb;25(2):166-173. doi: 10.1016/s1386-6346(02)00208-5. Hepatol Res. 2003. PMID: 12644053

4

Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma.

Tamori A, Nishiguchi S, Tanaka M, Kurooka H, Fujimoto S, Nakamura K, Shiomi S. Tamori A, et al. Among authors: nishiguchi s. Hepatol Res. 2003 May;26(1):77-80. doi: 10.1016/s1386-6346(03)00002-0. Hepatol Res. 2003. PMID: 12787809

5

Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan.

Orito E, Sugauchi F, Tanaka Y, Ichida T, Sata M, Tanaka E, Okanoue T, Sakugawa H, Watanabe H, Miyakawa H, Nishiguchi S, Kumada H, Ueda R, Mizokami M. Orito E, et al. Among authors: nishiguchi s. Intervirology. 2005;48(4):239-45. doi: 10.1159/000084601. Intervirology. 2005. PMID: 15920348

6

Timing of interferon therapy and sources of infection in patients with acute hepatitis C.

Ogata K, Ide T, Kumashiro R, Kumada H, Yotsuyanagi H, Okita K, Akahane Y, Kaneko S, Tsubouchi H, Tanaka E, Moriwaki H, Nishiguchi S, Kakumu S, Mizokami M, Iino S, Sata M. Ogata K, et al. Among authors: nishiguchi s. Hepatol Res. 2006 Jan;34(1):35-40. doi: 10.1016/j.hepres.2005.08.012. Epub 2005 Dec 15. Hepatol Res. 2006. PMID: 16359917

7

Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan.

Sugauchi F, Orito E, Ohno T, Tanaka Y, Ozasa A, Kang JH, Toyoda J, Kuramitsu T, Suzuki K, Tanaka E, Akahane Y, Ichida T, Izumi N, Inoue K, Hoshino H, Iino S, Yotsuyanagi H, Kakumu S, Tomita E, Okanoue T, Nishiguchi S, Murawaki Y, Hino K, Onji M, Yatsuhashi H, Sata M, Miyakawa Y, Ueda R, Mizokami M. Sugauchi F, et al. Among authors: nishiguchi s. Hepatol Res. 2006 Oct;36(2):107-14. doi: 10.1016/j.hepres.2006.06.001. Epub 2006 Sep 7. Hepatol Res. 2006. PMID: 16956789

8

Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.

Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Jomura H, Habu D, Sakaguchi H, Takeda T, Kawada N, Seki S, Shiomi S, Koh N, Nishiguchi S. Enomoto M, et al. Among authors: nishiguchi s. J Interferon Cytokine Res. 2007 Mar;27(3):201-7. doi: 10.1089/jir.2006.0140. J Interferon Cytokine Res. 2007. PMID: 17348818 Clinical Trial.

9

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts.

Okanoue T, Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, Takehara T, Kumada T, Tanaka E, Nishiguchi S, Izumi N, Sata M, Onji M, Yamada G, Okita K, Kumada H. Okanoue T, et al. Among authors: nishiguchi s. Hepatol Res. 2008 Jan;38(1):27-36. doi: 10.1111/j.1872-034X.2007.00217.x. Hepatol Res. 2008. PMID: 18039201

10

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study.

Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, Ishibashi H, Sakaida I, Kuriyama S, Ichida T, Onishi S, Toda G; Study Group of Intractable Liver Diseases for Research on a Specific Disease, Health Science Research Grant, Ministry of Health, Labour and Welfare of Japan. Iwasaki S, et al. Among authors: nishiguchi s. Hepatol Res. 2008 Jun;38(6):557-64. doi: 10.1111/j.1872-034X.2007.00305.x. Hepatol Res. 2008. PMID: 18452482

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

632 results

Search Page

Filters